Abiopharma

🔍 Duke John D (Director)

Company: HARVARD BIOSCIENCE INC (HBIO)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 75,000 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 180,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: See remarks
• REMARKS: Includes (a) an award granting 75,000 restricted stock units (RSUs) that will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 5,000 shares of common stock purchased on March 16, 2026, (c) an award of 50,000 RSUs that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person and (d) an award of 50,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported.